# US 2006/0154972 A1 · Amino acids with affinity for the alpha-2-delta-protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154972 A1
- Document ID: US20060154972A1
- Status: Published application
- Kind: A1
- Application number: 11/375,318
- Filed: 2006-03-14
- Published: 2006-07-13
- Earliest claimed: 2002-03-28
- Assignees: Pfizer Inc.
- Inventors: Nancy Barta; Jacob Schwarz; Andrew Thorpe; David Wustrow
- Web page: https://patentgrep.com/patent/US20060154972A1

## CPC

- C07C 229/08: the nitrogen atom of the amino group being further bound to hydrogen atoms
- A61K 31/195: having an amino group
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/24: of the sex hormones
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/32: Alcohol-abuse
- A61P 25/34: Tobacco-abuse
- A61P 25/36: Opioid-abuse
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07C 229/28: the carbon skeleton being saturated and containing rings
- C07C 229/34: the carbon skeleton containing six-membered aromatic rings
- C07C 2601/02: with a three-membered ring
- C07C 2601/04: with a four-membered ring
- C07C 2601/08: the ring being saturated
- C07C 2601/14: The ring being saturated
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention relates to certain β-amino acids that bind to the alpha-2-delta (α2δ) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.

## Claims

### Claim 1

(canceled)

### Claim 2

A compound of formula IA
or a pharmaceutically acceptable salt thereof;
wherein R1 is hydrogen or (C1-C3)alkyl optionally substituted with from one to five fluorine atoms;
R2 is hydrogen or (C1-C3)alkyl optionally substituted with from one to five fluorine atoms; and
R3 is (C1-C6)alkyl, (C3-C6)cycloalkyl, (C3-C6)cycloalkyl-(C1-C3)alkyl, phenyl, phenyl-(C1-C3)alkyl, or phenyl-N(H)—, wherein each alkyl is optionally substituted with from one to five fluorine atoms, and each phenyl is optionally substituted with from one to three substituents independently selected from chloro, fluoro, amino, nitro, cyano, (C1-C3)alkylamino, (C1-C3)alkyl optionally substituted with from one to three fluorine atoms, and (C1-C3)alkoxy optionally substituted with from one to three fluorine atoms;
with the proviso that when R1 is hydrogen, R2 is not hydrogen.

### Claim 3

(canceled)

### Claim 4 (depends on 2)

A compound according to claim 2 having the formula IA-1
or a pharmaceutically acceptable salt thereof;
wherein R3 is (C1-C6)alkyl, (C3-C6)cycloalkyl, (C3-C6)cycloalkyl-(C1-C3)alkyl, phenyl, phenyl-(C1-C3)alkyl, or phenyl-N(H)—, wherein each alkyl is optionally substituted with from one to five fluorine atoms, and each phenyl is optionally substituted with from one to three substituents independently selected from chloro, fluoro, amino, nitro, cyano, (C1-C3)alkylamino, (C1-C3)alkyl optionally substituted with from one to three fluorine atoms, and (C1-C3)alkoxy optionally substituted with from one to three fluorine atoms.

### Claim 5

(canceled)

### Claim 6 (depends on 2)

A compound according to claim 2 having the formula IA-2,
or a pharmaceutically acceptable salt thereof;
wherein R1 is hydrogen or (C1-C3)alkyl optionally substituted with from one to five fluorine atoms;
R2 is hydrogen or (C1-C3)alkyl optionally substituted with from one to five fluorine atoms; and
R3 is (C1-C6)alkyl, (C3-C6)cycloalkyl, (C3-C6)cycloalkyl-(C1-C3)alkyl, phenyl, phenyl-(C1-C3)alkyl, or phenyl-N(H)—, wherein each alkyl is optionally substituted with from one to five fluorine atoms, and each phenyl is optionally substituted with from one to three substituents independently selected from chloro, fluoro, amino, nitro, cyano, (C1-C3)alkylamino, (C1-C3)alkyl optionally substituted with from one to three fluorine atoms, and (C1-C3)alkoxy optionally substituted with from one to three fluorine atoms;
with the proviso that when R1 is hydrogen, R2 is not hydrogen.

### Claim at position 7

7-13. (canceled)

### Claim 14 (depends on 2)

A compound according to claim 2 selected from the following compounds and their pharmaceutically acceptable salts:
3-Amino-5-methyl-heptanonic acid;
3-Amino-5-methyl-nonanoic acid;
(3S,5R)-3-Amino-5-methyl-heptanoic acid;
(3S,5R)-3-Amino-5-methyl-nonanoic acid;
3-Amino-7-cyclopentyl-5-methyl-heptanoic acid;
3-Amino-7-cyclohexyl-5-methyl-heptanoic acid;
(3S,5R)-3-Amino-7-cyclopentyl-5-methyl-heptanoic acid;
(3S,5R)-3-Amino-7-cyclohexyl-5-methyl-heptanoic acid;
3-Amino-5-methyl-7-phenyl-heptanoic acid;
3-Amino-5-methyl-7-(2,4-difluoro-phenyl)-heptanoic acid;
3-Amino-8-(2,3-difluoro-phenyl)-5-methyl-octanoic acid;
3-Amino-8-(2,4-difluoro-phenyl)-5-methyl-octanoic acid;

### Claim 15 (depends on 2, 4, 6, 14)

A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any of claims 2, 4, 6 and 14, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 2, 4, 6, 14)

A method of treating a disorder or condition in a mammal, including a human, the disorder or condition selected from:
faintness attacks, fibromyalgia, hypokinesia, cranial disorders, hot flashes, essential tremor, chemical dependencies and addictions, including dependencies on or addictions to alcohol, amphetamines or amphetamine-like substances, caffeine, cannabis, cocaine, heroin, hallucinogens, tobacco, inhalants and aerosol propellants, nicotine, opioids, phenylglycidine derivatives, sedatives, hypnotics, benzodiazepines and other anxiolytics, and withdrawal symptoms associated with such dependencies or addictions; addictive behaviors including gambling; migraine, spasticity, arthritis, irritable bowel syndrome (IBS), chronic pain, acute pain, neuropathic pain, vascular headache, sinus headache, inflammatory disorders including rheumatoid arthritis, osteoarthritis, and psoriasis; diuresis, premenstrual syndrome, premenstrual dysphoric disorder, tinnitus, and gastric damage;
delirium, dementia, and amnestic and other cognitive or neurodegenerative disorders, such as Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, memory disorder, vascular dementia, and other dementias, including those due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple aetiologies; movement disorders such as akinesias, dyskinesias, including familial paroxysmal dyskinesias, spasticities, Tourette's syndrome, Scott syndrome, PALSYS and akinetic-rigid syndrome; extra-pyramidal movement disorders including medication-induced movement disorders, neuroleptic-induced Parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremour; Down's syndrome; demyelinating diseases including multiple sclerosis (MS) and amylolateral sclerosis (ALS), peripheral neuropathy, including diabetic and chemotherapy-induced-neuropathy, and postherpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia and other neuralgias; and cerebral vascular disorders due to acute or chronic cerebrovascular damage including cerebral infarction, subarachnoid haemorrhage or cerebral oedema;
sleep disorders including insomnia, drug-associated sleeplessness, REM sleep disorders, hypersomnia, narcolepsy, sleep-wake cycle disorders, sleep apnea syndromes, parasomnias, and sleep disorders associated with shift work and irregular work hours; and
mood disorders, including depression or depressive disorders, including single episodic or recurrent major depressive disorders, dysthymic disorders, depressive neurosis and neurotic depression, melancholic depression, including anorexia, weight loss, insomnia, early morning waking and psychomotor retardation, atypical depression or reactive depression, including increased appetite, hypersomnia, psychomotor agitation or irritability, seasonal affective disorder and pediatric depression; bipolar disorders or manic depression, including bipolar I disorder, bipolar II disorder and cyclothymic disorder; conduct disorder and disruptive behavior disorder; anxiety disorders, including panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias including specific animal phobias, social anxiety, social phobia, obsessive-compulsive disorder, stress disorders, including post-traumatic stress disorder and acute stress disorder, and generalized anxiety disorders; borderline personality disorder; schizophrenia and other psychotic disorders, including schizophreniform disorders, schizoaffective disorders, delusional disorders, brief psychotic disorders, shared psychotic disorders, psychotic disorders with delusions or hallucinations, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders including severe major depressive disorder; mood disorders associated with psychotic disorders including acute mania and depression associated with bipolar disorder, mood disorders associated with schizophrenia; behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder;
the method comprising administering to the mammal in need of such treatment a therapeutically effective amount of 3-amino-5-methyl-octanoic acid, (3S,5R)-3-amino-5-methyl-octanoic acid, or a compound according to any of claims 2, 4, 6 and 14, or a pharmaceutically acceptable salt thereof.
